CO90 Matching-Adjusted Indirect Comparison of Efficacy and Safety for Lebrikizumab, Dupilumab, and Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled or Non-eligible for Cyclosporine
Dec 1, 2024, 00:00
10.1016/j.jval.2024.10.166
https://www.valueinhealthjournal.com/article/S1098-3015(24)03029-8/fulltext
Title :
CO90 Matching-Adjusted Indirect Comparison of Efficacy and Safety for Lebrikizumab, Dupilumab, and Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled or Non-eligible for Cyclosporine
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)03029-8&doi=10.1016/j.jval.2024.10.166
First page :
Section Title :
Open access? :
No
Section Order :
11072